Fulminant hepatitis in a hepatitis B surface antigen‐positive patient with adult T‐cell leukemia‐lymphoma after mogamulizumab monotherapy-Reference-Cited by-同舟云学术

Fulminant hepatitis in a hepatitis B surface antigen‐positive patient with adult T‐cell leukemia‐lymphoma after mogamulizumab monotherapy

Published:2024-05-21 Issue: Volume: Page:
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Nakashima Takahiro¹,Kusumoto Shigeru¹²,Ishida Takashi³,Kato Chie¹,Hagiwara Shinya¹,Narita Tomoko¹,Masaki Ayako⁴,Ito Asahi¹,Ri Masaki¹,Komatsu Hirokazu¹,Inagaki Hiroshi⁴,Tanaka Yasuhito⁵^ORCID,Iida Shinsuke¹

Affiliation:

1. Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan

2. Department of Hematology and Cell Therapy Aichi Cancer Center Hospital Nagoya Japan

3. Department of Immunology Nagoya University Graduate School of Medicine Nagoya Japan

4. Department of Anatomic Pathology and Molecular Diagnostics Nagoya City University Graduate School of Medical Sciences Nagoya Japan

5. Department of Gastroenterology and Hepatology Faculty of Life Sciences Kumamoto University Kumamoto Japan

Abstract

AbstractWe report a case of fulminant hepatitis in a hepatitis B surface antigen (HBsAg)‐positive patient with aggressive adult T‐cell leukemia‐lymphoma who received monotherapy with an anti‐CCR4 monoclonal antibody, mogamulizumab, with decreased hepatitis B virus (HBV)‐ DNA levels by entecavir prophylaxis. Although HBV reactivation‐related hepatitis was considered in the differential diagnosis, the patient did not meet the conventional criteria for HBV reactivation and was finally diagnosed with drug‐induced hepatitis. Considering that the immunoenhancing effects of mogamulizumab can lead to HBV reactivation‐related hepatitis in HBsAg‐positive patients, we should differentiate drug‐induced hepatitis from HBV reactivation, especially in patients receiving immunomodulatory drugs, if HBV‐DNA levels are reduced by antiviral prophylaxis.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.14057

Reference22 articles.

1. Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study

2. Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study

3. Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

4. Mortality Secondary to Fulminant Hepatic Failure in Patients with Prior Resolution of Hepatitis B Virus Infection in Japan